News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Progenics Pharmaceuticals, Inc., Wyeth Say Bowel Drug Gets Canadian OK
April 1, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
April 1 (Reuters) - Progenics Pharmaceuticals Inc and partner Wyeth said their bowel drug, Relistor, received marketing clearance from Canadian authorities, sending Progenics' shares up 7 percent before the bell.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
MORE ON THIS TOPIC
Manufacturing
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
October 29, 2026
·
2 min read
·
Nick Paul Taylor
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
·
4 min read
·
Heather McKenzie
Insights
Australia’s clinical trial advantage gains ground amid U.S. uncertainty
October 26, 2026
·
4 min read
·
Jennifer C. Smith-Parker
